Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
Objective
To summarize the efficacy and safety results of the long-term extension study following UNITI-1, UNITI-2, and IM-UNITI. The following is based on unpublished data.68
Findings
Study Design
▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
- ▬
Limitations
▬
Summary
▬
- SUMMARY OF THE IM-UNITI EXTENSION STUDY - Ustekinumab (Stelara)SUMMARY OF THE IM-UNITI EXTENSION STUDY - Ustekinumab (Stelara)
- CONCLUSIONS - Glycerol Phenylbutyrate (Ravicti)CONCLUSIONS - Glycerol Phenylbutyrate (Ravicti)
- Homo sapiens thioredoxin related transmembrane protein 2 (TMX2), transcript vari...Homo sapiens thioredoxin related transmembrane protein 2 (TMX2), transcript variant 6, mRNAgi|1890359023|ref|NM_001347891.2|Nucleotide
- Rattus norvegicus fucosyltransferase 4 (Fut4), mRNARattus norvegicus fucosyltransferase 4 (Fut4), mRNAgi|309243083|ref|NM_022219.3|Nucleotide
- Rattus norvegicus vomeronasal 2 receptor, 18 (Vom2r18), mRNARattus norvegicus vomeronasal 2 receptor, 18 (Vom2r18), mRNAgi|1937866099|ref|NM_173318.2|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...